Page 44 - TD-4-1

Tumor Discovery CDK4/6 inhibitor resistance in breast cancer

open-label, multicentre, phase 3 trial. Lancet Oncol. endocrine therapy in metastatic breast cancer. N Engl J Med.
2022;23(11):1367-1377. 2024;391:2110-2122.
doi: 10.1016/S1470-2045(22)00555-1 doi: 10.1056/NEJMoa2407086
42. Ye M, Xu H, Ding J, Jiang L. Therapy for hormone receptor- 49. McCartney A, Migliaccio I, Bonechi M, et al. Mechanisms of
positive, human epidermal growth receptor 2-negative resistance to CDK4/6 inhibitors: Potential implications and
metastatic breast cancer following treatment progression via biomarkers for clinical practice. Front Oncol. 2019;9:666.
CDK4/6 inhibitors: A literature review. Breast Cancer (Dove
Med Press). 2024;16:181-197. doi: 10.3389/fonc.2019.00666
50. Johnston S, Emde A, Barrios C, et al. Cyclin-dependent
doi: 10.2147/BCTT.S438366
kinase 4 and 6 (CDK4/6) inhibitors: Existing and emerging
43. Müller VJE. Current and upcoming treatment strategies differences. JNCI Cancer Spectr. 2023;7(4):pkad045.
after CDK4/6 inhibitors for patients with ER+/HER2-
advanced. Breast Cancer. 2023;11(1):33-43. doi: 10.1093/jncics/pkad045
44. Kalinsky K, Accordino MK, Chiuzan C, et al. Randomized 51. Thill M, Schmidt M. Management of adverse events
phase II trial of endocrine therapy with or without ribociclib during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-
after progression on cyclin-dependent kinase 4/6 inhibition based treatment in breast cancer. Ther Adv Med Oncol.
in hormone receptor-positive, human epidermal growth 2018;10:1758835918793326.
factor receptor 2-negative metastatic breast Cancer: doi: 10.1177/1758835918793326
MAINTAIN trial. J Clin Oncol. 2023;41(24):4004-4013.
52. Gelbert LM, Cai S, Lin X, et al. Preclinical characterization
doi: 10.1200/JCO.22.02392 of the CDK4/6 inhibitor LY2835219: In-vivo cell cycle-
45. Ma J, Chan JJ, Toh CH, Yap YS. Emerging systemic therapy dependent/independent anti-tumor activities alone/
options beyond CDK4/6 inhibitors for hormone receptor- in combination with gemcitabine. Invest New Drugs.
positive HER2-negative advanced breast cancer. NPJ Breast 2014;32(5):825-837.
Cancer. 2023;9(1):74. doi: 10.1007/s10637-014-0120-7
doi: 10.1038/s41523-023-00578-3 53. Xu B, Zhang Q, Zhang P, et al. Dalpiciclib or placebo plus
46. Mittal A, Molto Valiente C, Tamimi F, et al. Filling the gap fulvestrant in hormone receptor-positive and HER2-
after CDK4/6 inhibitors: Novel endocrine and biologic negative advanced breast cancer: A randomized, phase 3
treatment options for metastatic hormone receptor positive trial. Nat Med. 2021;27(11):1904-1909.
breast cancer. Cancers (Basel). 2023;15(7):2015. doi: 10.1038/s41591-021-01562-9
doi: 10.3390/cancers15072015 54. Sheikh MS, Satti SA. The emerging CDK4/6 inhibitor for
47. Benvenuti C, Gaudio M, Jacobs F, et al. Clinical review on the breast cancer treatment. Mol Cell Pharmacol. 2021;13(3):9-12.
management of breast cancer visceral crisis. Biomedicines. 55. Long F, He Y, Fu H, et al. Preclinical characterization of
2023;11(4):1083. SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human
doi: 10.3390/biomedicines11041083 tumor xenograft models. Cancer Sci. 2019;110(4):1420-1430.
48. Bardia A, Hu X, Dent R, et al. Trastuzumab deruxtecan after doi: 10.1111/cas.13957

Volume 4 Issue 1 (2025) 36 doi: 10.36922/td.7107